



## MiCardia Corporation Appoints Maurice Buchbinder as its Chief Medical Officer

**MiCardia Corporation** — October 26, 2010 — (Irvine, California) announced today the appointment of Maurice Buchbinder, M.D. F.A.C.C, F.S. C.A.I., as its Chief Medical Officer. This appointment expands his activities with MiCardia as he currently serves the Company as Chair of the Scientific Advisory Board and a member of the Board of Directors.

"To date, Dr Buchbinder's involvement with MiCardia as a Board Member and Chairman of our Scientific Advisory Board he has been a great asset. In this additional role he will provide leadership in the further development of the Company's TMVR (Transcatheter Mitral Valve Repair) catheter program. We welcome Dr Buchbinder's additional involvement in the Company's research and development efforts" said Don Rohrbaugh, MiCardia's Chief Executive Officer.

After graduating medical school from McGill University in Montreal, Canada, Dr. Buchbinder moved to Stanford University where he began his fellowship training in cardiovascular medicine. He began practicing medicine in 1983, sold his first company/patented device at the age of thirty-four and has helped to pioneer the field of interventional cardiology. He has been involved in the development of many devices, now used routinely in the practice of interventional medicine. His interest for many years has focused on improving the treatment and outcomes in patients with coronary artery disease. He holds patents on over twenty devices, focusing on percutaneous balloons, stents, atherectomy devices and structural heart disease. Over the past twenty-five years Dr. Buchbinder has been the founder of several successful start-ups and a scientific advisor for many major cardiovascular companies in the field.

More recently, Dr. Buchbinder has begun working with a number of innovations in the percutaneous treatment of various valve conditions, looking for effective alternatives to more invasive open heart surgery. Dr. Buchbinder brings a wealth of experience to support MiCardia's focus on the development of therapeutic heart valve products, particularly for the company's development of its Transcatheter mitral valve repair system.

### About MiCardia and enCor

MiCardia is a privately held medical device company currently preparing for the commercialization of its first series of products, enCor™, in the European Union. enCor is a unique device that surgically treats mitral valve regurgitation. enCor utilizes the company's patented technology, Dynaplasty™, to provide a "second chance" to the patient who develops recurrent regurgitation. enCor can be activated to physiologically adjust the mitral valve leaflets to resolve regurgitation, minimally invasively, weeks to years later, without the need for the risk and cost of redo surgery.

The company's next generation product will provide the capability to implant the Dynaplasty Technology interventionally. The enCorTC, currently in development, will provide a non-surgical, lower risk method to mitral valve repair.

For further information, please visit [www.micardia.com](http://www.micardia.com) or contact:

**Robin Gibbs, Director of Communications and Marketing**

+949-951-4888

[rgibbs@micardia.com](mailto:rgibbs@micardia.com)

The MiCardia Dynamic Annuloplasty System is not currently available in the USA. Clinical evaluation is in progress. Not available for sale. MiCardia, Dynaplasty and Dynamic Annuloplasty System are registered trademarks of MiCardia Corporation. All rights reserved.